Current Report Filing (8-k)
May 10 2023 - 5:11PM
Edgar (US Regulatory)
0001551152
false
Common Stock, $0.01 Par Value
ABBV
0001551152
2023-05-05
2023-05-05
0001551152
us-gaap:CommonStockMember
exch:XNYS
2023-05-05
2023-05-05
0001551152
exch:XCHI
us-gaap:CommonStockMember
2023-05-05
2023-05-05
0001551152
abbv:SeniorNotes1.500Percentdue2023Member
exch:XNYS
2023-05-05
2023-05-05
0001551152
abbv:SeniorNotes1.375Percentdue2024Member
exch:XNYS
2023-05-05
2023-05-05
0001551152
abbv:SeniorNotes1.250Percentdue2024Member
exch:XNYS
2023-05-05
2023-05-05
0001551152
abbv:SeniorNotes0.750Percentdue2027Member
exch:XNYS
2023-05-05
2023-05-05
0001551152
abbv:SeniorNotes2.125Percentdue2028Member
exch:XNYS
2023-05-05
2023-05-05
0001551152
abbv:SeniorNotes2.625Percentdue2028Member
exch:XNYS
2023-05-05
2023-05-05
0001551152
abbv:SeniorNotes2.125Percentdue2029Member
exch:XNYS
2023-05-05
2023-05-05
0001551152
abbv:SeniorNotes1.250Percentdue2031Member
exch:XNYS
2023-05-05
2023-05-05
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to
Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date of Report (Date of earliest event
reported): May 5, 2023
ABBVIE
INC.
(Exact name of registrant as specified in its charter)
Delaware |
|
001-35565 |
|
32-0375147 |
(State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
1 North Waukegan Road
North Chicago, Illinois 60064-6400
(Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (847) 932-7900
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common
Stock, $0.01 Par Value |
|
ABBV |
|
New
York Stock Exchange Chicago
Stock Exchange |
1.500%
Senior Notes due 2023 |
|
ABBV23B |
|
New
York Stock Exchange |
1.375%
Senior Notes due 2024 |
|
ABBV24 |
|
New
York Stock Exchange |
1.250%
Senior Notes due 2024 |
|
ABBV24B |
|
New
York Stock Exchange |
0.750%
Senior Notes due 2027 |
|
ABBV27 |
|
New
York Stock Exchange |
2.125%
Senior Notes due 2028 |
|
ABBV28 |
|
New
York Stock Exchange |
2.625%
Senior Notes due 2028 |
|
ABBV28B |
|
New
York Stock Exchange |
2.125%
Senior Notes due 2029 |
|
ABBV29 |
|
New
York Stock Exchange |
1.250%
Senior Notes due 2031 |
|
ABBV31 |
|
New
York Stock Exchange |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Common Stock, $0.01 Par Value |
ABBV |
| Item
5.07 | Submission
of Matters to a Vote of Security Holders. |
AbbVie
Inc. (“AbbVie”) held its Annual Meeting of Stockholders on May 5, 2023. The following is a summary of the matters voted
on at that meeting.
|
(1) |
The
stockholders elected AbbVie’s Class II Directors with terms expiring in 2026, as follows: |
Name |
|
For |
|
Against |
|
Broker
Non-Votes |
Robert
J. Alpern |
|
1,142,062,843 |
|
20,689,813 |
|
251,363,568 |
Melody
B. Meyer |
|
1,247,333,998 |
|
4,243,832 |
|
251,363,568 |
Frederick
H. Waddell |
|
1,208,836,612 |
|
14,319,844 |
|
251,363,568 |
|
(2) |
The
stockholders ratified the appointment of Ernst & Young LLP as AbbVie’s independent registered public accounting firm
for 2023, as follows: |
For |
|
Against |
|
Abstain |
1,486,053,290 |
|
18,676,821 |
|
3,224,042 |
|
(3) |
The
stockholders approved, on an advisory basis, the compensation of AbbVie’s named executive officers listed in the proxy statement
for the 2023 annual meeting, as follows: |
For |
|
Against |
|
Abstain |
|
Broker
Non-Votes |
1,137,389,680 |
|
109,281,658 |
|
9,919,247 |
|
251,363,568 |
|
(4) |
The
stockholders did not approve the management proposal regarding amendment of the certificate of incorporation to eliminate supermajority
voting, as follows: |
For |
|
Against |
|
Abstain |
|
Broker
Non-Votes |
1,241,106,832 |
|
11,289,016 |
|
4,194,737 |
|
251,363,568 |
|
(5) |
The
stockholders approved a stockholder proposal to implement simple majority voting, as follows: |
For |
|
Against |
|
Abstain |
|
Broker
Non-Votes |
668,497,335 |
|
581,300,391 |
|
6,792,859 |
|
251,363,568 |
|
(6) |
The
stockholders did not approve a stockholder proposal to issue an annual report on political spending, as follows: |
For |
|
Against |
|
Abstain |
|
Broker
Non-Votes |
187,829,409 |
|
1,052,110,624 |
|
16,650,552 |
|
251,363,568 |
|
(7) |
The
stockholders did not approve a stockholder proposal to issue an annual report on lobbying, as follows: |
For |
|
Against |
|
Abstain |
|
Broker
Non-Votes |
448,957,091 |
|
787,145,991 |
|
20,487,503 |
|
251,363,568 |
|
(8) |
The
stockholders did not approve a stockholder proposal to issue an annual report on patent process, as follows: |
For |
|
Against |
|
Abstain |
|
Broker
Non-Votes |
363,777,601 |
|
867,061,281 |
|
25,751,703 |
|
251,363,568 |
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
ABBVIE
INC. |
|
|
|
|
Date: |
May 10,
2023 |
By: |
/s/
Perry C. Siatis |
|
|
|
Perry
C. Siatis |
|
|
|
Executive
Vice President, General Counsel and Corporate Secretary |
AbbVie (NYSE:ABBV)
Historical Stock Chart
From May 2024 to Jun 2024
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Jun 2023 to Jun 2024